Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CPT1A | P50416 | 2/20 | 0.47 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5221118 | 0.89 | LPAR1 (0.51) | LPAR1L3MBTL1MAPK1MEN1KMT2A | |
| SCHEMBL5354933 | 0.82 | L3MBTL1 (0.47) | L3MBTL1MAPTMAPK1LMNASMN1; SMN2 | |
| SCHEMBL5215989 | 0.81 | MAPT (0.63) | L3MBTL1MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL5215864 | 0.81 | MAPT (0.43) | L3MBTL1CPT1ACPT1BMAPTLMNA | |
| SCHEMBL5219012 | 0.77 | L3MBTL1 (0.45) | L3MBTL1MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL5221451 | 0.77 | XIAP (0.39) | L3MBTL1MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL5400004 | 0.76 | MAPT (0.44) | L3MBTL1MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL5220598 | 0.76 | HSD17B10 (0.50) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5217930 | 0.76 | KCNJ6 (0.48) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5219021 | 0.75 | MAPT (0.42) | L3MBTL1MAPTLMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101115528-A | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogs thereof | ACHILLION PHARMACEUTICALS INC (US) | 2008-01-30 | — | — | CN | claimed |
| EP-1809380-A2 | INHIBITORS OF HIV-1 CAPSID FORMATION: SUBSTITUTED ARYL AMINOMETHYL THIAZOLE UREAS AND ANALOGUES THEREOF | Achillion Pharmaceuticals, Inc. (US) | 2007-07-25 | — | — | EP | claimed |
| US-7183300-B2 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | UNIVERSITY OF MARYLAND BALTIMORE COUNTY | 2007-02-27 | — | — | US | claimed |
| WO-2006053323-A2 | INHIBITORS OF HIV-1 CAPSID FORMATION: SUBSTITUTED ARYL AMINOMETHYL THIAZOLE UREAS AND ANALOGUES THEREOF | ACHILLION PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20060100232-A1 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | ACHILLION PHARMACEUTICAL, INC. | 2006-05-11 | — | — | US | claimed |
| CN-101115528-A | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogs thereof | ACHILLION PHARMACEUTICALS INC (US) | 2008-01-30 | — | — | CN | disclosed |
| US-7183300-B2 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | UNIVERSITY OF MARYLAND BALTIMORE COUNTY | 2007-02-27 | — | — | US | disclosed |
| US-7183300-B2 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | UNIVERSITY OF MARYLAND BALTIMORE COUNTY | 2007-02-27 | — | — | US | disclosed |
| US-7183300-B2 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | UNIVERSITY OF MARYLAND BALTIMORE COUNTY | 2007-02-27 | — | — | US | disclosed |
| US-20060100232-A1 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | ACHILLION PHARMACEUTICAL, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100232-A1 | Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof | ZC3HAV1, CD4, ACIN1 | LPAR1 4677/4885L3MBTL1 303/4885CPT1A 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.